237 related articles for article (PubMed ID: 27815354)
1. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
[No Abstract] [Full Text] [Related]
2. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.
Gammaitoni L; Giraudo L; Leuci V; Todorovic M; Mesiano G; Picciotto F; Pisacane A; Zaccagna A; Volpe MG; Gallo S; Caravelli D; Giacone E; Venesio T; Balsamo A; Pignochino Y; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2013 Aug; 19(16):4347-58. PubMed ID: 23794732
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.
Sangiolo D; Mesiano G; Gammaitoni L; Leuci V; Todorovic M; Giraudo L; Cammarata C; Dell'Aglio C; D'Ambrosio L; Pisacane A; Sarotto I; Miano S; Ferrero I; Carnevale-Schianca F; Pignochino Y; Sassi F; Bertotti A; Piacibello W; Fagioli F; Aglietta M; Grignani G
Cancer Res; 2014 Jan; 74(1):119-29. PubMed ID: 24356422
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Mesiano G; Grignani G; Fiorino E; Leuci V; Rotolo R; D'Ambrosio L; Salfi C; Gammaitoni L; Giraudo L; Pisacane A; Butera S; Pignochino Y; Basiricó M; Capozzi F; Sapino A; Aglietta M; Sangiolo D
Oncoimmunology; 2018; 7(11):e1465161. PubMed ID: 30393581
[TBL] [Abstract][Full Text] [Related]
7. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma.
Li H; Huang L; Liu L; Wang X; Zhang Z; Yue D; He W; Fu K; Guo X; Huang J; Zhao X; Zhu Y; Wang L; Dong W; Yan Y; Xu L; Gao M; Yang S; Zhang Y
Cancer Immunol Immunother; 2017 Mar; 66(3):299-308. PubMed ID: 27889798
[TBL] [Abstract][Full Text] [Related]
8. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
9. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
[TBL] [Abstract][Full Text] [Related]
10. Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients.
Zhang Y; Zhu Y; Zhao E; He X; Zhao L; Wang Z; Fu X; Qi Y; Ma B; Song Y; Gao Q
Immunotherapy; 2017 Nov; 9(14):1165-1174. PubMed ID: 29067881
[TBL] [Abstract][Full Text] [Related]
11. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
12. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y
Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
14. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
16. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
17. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
18. Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.
Ryu JI; Han MH; Cheong JH; Kim JM; Kim CH
Immunotherapy; 2017 Mar; 9(5):411-421. PubMed ID: 28357913
[TBL] [Abstract][Full Text] [Related]
19. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
